What is Protembis?
Founded in 2013, Protembis operates at the intersection of interventional cardiology and neuroprotection. The company specializes in the development of innovative medical devices designed to reduce the incidence of significant brain lesions and stroke during high-risk cardiology procedures. Its core technology, the ProtEmbo Cerebral Protection System, addresses a critical unmet need in the TAVR market by providing a robust barrier against embolic debris. With a strategic focus on patient outcomes and procedural safety, Protembis has established itself as a key player in the European medtech ecosystem, supported by ongoing clinical studies that validate the efficacy of its proprietary cerebral protection solutions.
How much funding has Protembis raised?
Protembis has raised a total of $43.6M across 2 funding rounds:
Series A
$10M
Series B
$33.6M
Series A (2018): $10M, investors not publicly disclosed
Series B (2024): $33.6M led by XGEN Venture SGR SpA, coparion, and Segulah Medical Acceleration
Key Investors in Protembis
XGEN Venture SGR SpA
An Italian alternative investment fund manager specializing in early-stage research and development within the life sciences sector, focused on building next-generation medical ventures.
coparion
A venture capital fund dedicated to supporting young German technology companies with a long-term perspective and a focus on sustainable growth.
Segulah Medical Acceleration
A specialized investor focused on transforming medical device and health technology companies into market leaders through deep industry expertise and a Nordic-centric network.
What's next for Protembis?
With the successful closure of this major enterprise-level funding, Protembis is poised to transition from clinical validation to broader market preparation. The strategic roadmap likely involves scaling manufacturing capabilities and expanding the clinical evidence base required for regulatory approval in key global markets. As the company continues to refine its ProtEmbo system, the focus will remain on demonstrating long-term clinical benefits for patients undergoing TAVR. This capital infusion provides the necessary runway to navigate the complex regulatory environment and solidify the company's competitive advantage in the rapidly evolving field of cardiovascular neuroprotection.
See full Protembis company page
